Some of the potential therapeutic targets exist not only in the malignant tissue but also in the physiological, such as Glypican-3 (GPC-3), which is overexpressed in HCC and infrequently in normal tissues, as well as AFP. The gene discussed is GPC3; the disease is hepatocellular carcinoma.